After-Hours Stock Movers 2/10: (AMKR) (FLDM) (RNG) Higher; (YAYO) (LOGC) (WORK) Lower (more...)

February 10, 2020 6:01 PM

YayYo, Inc. (NASDAQ: YAYO) 45% LOWER; today announced its intention to voluntarily delist its common stock from the NASDAQ Stock Market (NASDAQ) effective on February 20, 2020. The Company expects that its common stock will be approved for quotation on the OTCQB from and after that date. The Company has elected to effect the voluntary delisting of its common stock after discussions with NASDAQs staff and based on the determination of the Companys board of directors that voluntarily delisting the common stock from the NASDAQ is in the best interests of the Company and its stockholders. NASDAQ has advised the Company that it believes that the Company has failed the conditions for continued listing of its common stock set forth in Listing Rule 5250(a). The voluntary delisting will permit the Company to operate its business free from restrictions imposed by NASDAQ rules and the conditions applicable to the listing of the Companys common stock on the NASDAQ.

LogicBio Therapeutics, Inc. (Nasdaq: LOGC) 26.3% LOWER; announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Investigational New Drug (IND) submission for LB-001 for the treatment of methylmalonic acidemia (MMA) pending the resolution of certain clinical and nonclinical questions. The Company submitted the IND in January 2020 to support the initiation of a Phase 1/2 clinical trial in patients with MMA. LogicBio expects that the FDA questions will be provided in writing within 30 days. LogicBio plans to work closely with the FDA to resolve these questions as quickly as possible.

Amkor Technology (NASDAQ: AMKR) 15.6% HIGHER; reported Q4 EPS of $0.41, $0.19 better than the analyst estimate of $0.22. Revenue for the quarter came in at $1.18 billion versus the consensus estimate of $1.1 billion. Amkor Technology sees Q1 2020 EPS of $0.09-$0.24, versus the consensus of $0.08. Amkor Technology sees Q1 2020 revenue of $1.08-1.16 billion, versus the consensus of $1.01 billion.

Pyxus International (NYSE: PYX) 15.4% LOWER; reported Q3 EPS of ($2.40), versus ($0.56) reported last year. Revenue for the quarter came in at $363.3 million, versus $524.49 million reported last year.

Fluidigm (NASDAQ: FLDM) 10.8% HIGHER; reported Q4 EPS of ($0.18), $0.01 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $32.4 million versus the consensus estimate of $30.84 million.

Slack (NYSE: WORK) 7.8% LOWER; After gaining 15% intra-day on reports of an IBM deal, the company said IBM has been its largest customer and it is not updating its guidance.

RCI Hospitality Holdings, Inc. (NASDAQ: RICK) 6.6% HIGHER; RCI to File 10-K, Hold Call and Meet Management; Board Ups Buy Back Authorization $10 Million.

Moderna, Inc. (Nasdaq: MRNA) 6.4% LOWER; announced that it has commenced an underwritten public offering of $500 million in shares of common stock. In addition, Moderna expects to grant the underwriters a 30-day option to purchase up to an additional $75 million in shares of common stock in connection with the public offering. All shares of common stock will be offered by Moderna.

Callaway Golf (NYSE: ELY) 6% LOWER; reported Q4 EPS of ($0.26), $0.02 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $311.9 million versus the consensus estimate of $305.3 million. Callaway Golf sees Q1 2020 EPS of $0.41-$0.47, versus the consensus of $0.67. Callaway Golf sees Q1 2020 revenue of $501-516 million, versus the consensus of $543.14 million. Callaway Golf sees FY2020 EPS of $0.82-$0.94, versus the consensus of $1.21. Callaway Golf sees FY2020 revenue of $1.75-1.78 billion, versus the consensus of $1.78 billion.

Theravance Biopharma, Inc. (NASDAQ: TBPH) 5% LOWER; intends to offer $150.0 million of ordinary shares in an underwritten public offering. Theravance Biopharma also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of additional ordinary shares. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

MercadoLibre (NASDAQ: MELI) 3.9% LOWER; reported Q4 EPS of ($1.11), $0.45 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $674.3 million versus the consensus estimate of $646.82 million.

Mimecast Limited (NASDAQ: MIME) 3.7% LOWER; reported Q3 EPS of $0.14, $0.02 better than the analyst estimate of $0.12. Revenue for the quarter came in at $110.2 million versus the consensus estimate of $108.11 million. Mimecast Limited sees Q4 2020 revenue of $112.9-114 million, versus the consensus of $112.8 million.

Ringcentral, Inc. (NYSE: RNG) 3% HIGHER; reported Q4 EPS of $0.22, $0.01 better than the analyst estimate of $0.21. Revenue for the quarter came in at $253 million versus the consensus estimate of $239.45 million. Ringcentral, Inc. sees FY2020 EPS of $0.93-$0.94, versus the consensus of $0.93. Ringcentral, Inc. sees FY2020 revenue of $1.125-1.35 billion, versus the consensus of $1.1 billion. Ringcentral, Inc. sees Q1 2020 EPS of $0.18-$0.19, versus the consensus of $0.18. Ringcentral, Inc. sees Q1 2020 revenue of $257-259 million, versus the consensus of $249.2 million.

XPO Logistics (NYSE: XPO) 2.2% HIGHER; reported Q4 EPS of $1.12, $0.11 better than the analyst estimate of $1.01. Revenue for the quarter came in at $4.14 billion versus the consensus estimate of $4.23 billion.

Categories

Special Reports

Next Articles